Digest Network Come funziona
Network
/
Società
Na
Non verificato

Navigator Medicines, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato del lavoroSalute

4 comunicati stampa

Guarda tutti i comunicati
29/05/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
Industria
Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
Fonte
Navigator Medicines, Inc.
Emittente
Business Wire
1.00
0
05/03/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Navigator Medicines to Present Data at the American Academy of Dermatology (AAD) Annual Meeting
Fonte
Navigator Medicines, Inc.
Emittente
Business Wire
1.00
0
11/02/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors
Fonte
Navigator Medicines, Inc.
Emittente
Business Wire
1.00
0
27/08/2024
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
Fonte
Navigator Medicines, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0